NCT00686010View on ClinicalTrials.gov

Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia

PHASE2CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

January 31, 2001

Study Completion Date

June 30, 2001

Conditions
Type II Hyperlipidaemia
Interventions
DRUG

Placebo

Placebo tablet, 3 tablets, oral, once daily after breakfast

DRUG

JTT-705 300mg

JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.

DRUG

JTT-705 600mg

JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast

DRUG

JTT-705 900mg

JTT-705 tablet, 3 tablets, oral, once daily, after breakfast

Trial Locations (1)

Unknown

Amsterdam, Utrecht, Rotterdam, Nijmegen, Arnhem, Groningen, Dordrecht, Hoorn, Groningen, Amsterdam

All Listed Sponsors
lead

Japan Tobacco Inc.

INDUSTRY

NCT00686010 - Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia | Biotech Hunter | Biotech Hunter